from admin | Feb 21, 2026 | News
Hebert A. Hyperhidrosis. Presented at: South Beach Symposium; February 5–7, 2026; Miami Beach, Florida. Hyperhidrosis, a condition characterized by excessive sweating of the armpits, palms, soles, and face, typically develops in children...
from admin | Jan 1, 2026 | News
De Rosas EC, et al. JAMA Dermatol. 2026 Mycophenolate mofetil has been shown to be equally effective and more tolerable than methotrexate in the treatment of juvenile localized scleroderma. Juvenile localized scleroderma (JLS), also known as morphea, is a...
from admin | Nov 25, 2025 | News
Kobylinski KC, et al. Oral ivermectin is safe in children weighing 5 to less than 15 kg — a multicenter trial. Presented at: American Society of Tropical Medicine & Hygiene Annual Meeting; Nov. 9-13, 2025; Toronto. Children weighing less than 15 kg are...
from admin | Nov 24, 2025 | News
Koselugo (selumetinib) for the treatment of type 1 neurofibromatosis with symptomatic and inoperable plexiform neurofibromas is now approved in the United States, the European Union, and Asia for adults. The approval of Koselugo was based on data...
from admin | Oct 3, 2025 | News
The FDA has approved remibrutinib (Rhapsido, Novartis), a Bruton's tyrosine kinase inhibitor, as the first oral treatment for adults with persistent chronic spontaneous urticaria (CSU) resistant to H1 antihistamine therapy. CSU affects approximately...
from admin | Oct 2, 2025 | News
F Xiang, et al. Abstract #LBA-213. Presented at: European Academy of Dermatology and Venereology Congress; Sept. 17-20, 2025; Paris. Denifanstat, a fatty acid synthase inhibitor, has been shown to be effective in the treatment of acne vulgaris caused by...
